<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31629700</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7786</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>315</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Jan</Month>
              <Day>05</Day>
            </PubDate>
          </JournalIssue>
          <Title>Chemico-biological interactions</Title>
          <ISOAbbreviation>Chem Biol Interact</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Saxagliptin protects against hypoxia-induced damage in H9c2 cells.</ArticleTitle>
        <Pagination>
          <StartPage>108864</StartPage>
          <MedlinePgn>108864</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2019.108864</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0009-2797(19)31447-4</ELocationID>
        <Abstract>
          <AbstractText>Type II diabetes is recognized as a major risk factor for death due to cardiovascular complications such as coronary heart disease (CHD), but the complex interplay between these two diseases remains poorly understood. Suppression of oxidative stress, apoptosis, and inflammation of endothelial cells is a valuable treatment strategy to prevent or halt the progression of CHD. In the present study, we used real-time polymerase chain reaction (PCR), Western blot analysis, and enzyme linked immunosorbent assay (ELISA) to investigate the effects of saxagliptin on hypoxia-inducible factors. Our findings demonstrate that saxagliptin can significantly improve cell viability in H9c2 cells as well as reduce hypoxia-induced oxidative damage and loss of mitochondrial membrane potential. Saxagliptin reduced hypoxia-induced NADPH oxidase 4 (NOX 4). We also show that saxagliptin can reduce the expression of matrix metallopeptidase-2 (MMP-2) and matrix metallopeptidase-9 (MMP-9), two important degradative enzymes. Saxagliptin also suppressed hypoxia-induced expression of high mobility group box-1 protein (HMGB1), a key inflammatory cytokine. Finally, we show that saxagliptin can exert atheroprotective effects by reducing the expression of myeloid differential protein-88 (MyD88) and increasing the expression of nuclear factor erythroid-2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1). Thus, saxagliptin shows promise as a treatment against diabetes-associated CHD.</AbstractText>
          <CopyrightInformation>Copyright Â© 2019 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lili</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The People's Hospital of Longhua, Shenzhen, 518109, China. Electronic address: drzhanglili@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Xiaogui</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The People's Hospital of Longhua, Shenzhen, 518109, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Guowei</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiac Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China. Electronic address: zhangguowei5271@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yingying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tian</LastName>
            <ForeName>Jiali</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>17</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Ireland</Country>
        <MedlineTA>Chem Biol Interact</MedlineTA>
        <NlmUniqueID>0227276</NlmUniqueID>
        <ISSNLinking>0009-2797</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D053594">Myeloid Differentiation Factor 88</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.14.14.18</RegistryNumber>
          <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 1.6.3.-</RegistryNumber>
          <NameOfSubstance UI="D000074663">NADPH Oxidase 4</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.24</RegistryNumber>
          <NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.24.35</RegistryNumber>
          <NameOfSubstance UI="D020780">Matrix Metalloproteinase 9</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051547" MajorTopicYN="N">Heme Oxygenase-1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020780" MajorTopicYN="N">Matrix Metalloproteinase 9</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053594" MajorTopicYN="N">Myeloid Differentiation Factor 88</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D032383" MajorTopicYN="N">Myocytes, Cardiac</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000074663" MajorTopicYN="N">NADPH Oxidase 4</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="N">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018384" MajorTopicYN="N">Oxidative Stress</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DPP-4</Keyword>
        <Keyword MajorTopicYN="N">Inflammation</Keyword>
        <Keyword MajorTopicYN="N">Ischemic heart disease</Keyword>
        <Keyword MajorTopicYN="N">MyD88</Keyword>
        <Keyword MajorTopicYN="N">Saxagliptin</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>8</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>2</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31629700</ArticleId>
        <ArticleId IdType="doi">10.1016/j.cbi.2019.108864</ArticleId>
        <ArticleId IdType="pii">S0009-2797(19)31447-4</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
